Drug Trial Radar · NCT01304927
Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial
Last checked: Nov 19, 2026Latest source record: Jun 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
307
Actual
Start
Feb 2011
Primary completion
Dec 2014
Study completion May 2016
Sponsor
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Today, it is evident that vitamin D (VD) has more widespread effects than the classical actions related to bone mineralization and calcium homeostasis1. VD deficiency results in impaired reproductive performance in various species of animals, and recently the investigators have shown that the VD receptor (VDR), activating (CYP2R1, CYP27A1, CYP27B1) and inactivating (CYP24A1) enzymes are expressed in the human testis, epididymis, seminal vesicle, prostate and spermatozoa. Our following functional studies showed that VD increases intracellular calcium in mature spermatozoa, and hence may be important not only for spermatogenesis but also for sperm maturation. A new, and yet unpublished cross sectional study of 300 young healthy Danish men showed that men with lower levels of serum VD have significantly lower number of normally developed and motile spermatozoa. Hitherto, most cases of male infertility have been classified as "idiopathic", and infertile couples have been referred to symptomatic treatment at infertility clinics. These fertility treatments are often physically demanding for the female partner as well as expensive for the health care system. Any treatment that might improve semen quality of involuntary infertile men would be beneficial both for the infertile couples and the society in general. Our findings that VD may play a role for human semen quality have not yet been tested clinically. However, if VD supplementation proves efficient this opens for the first time for a causal, safe and cheap treatment of at least some cases of "idiopathic" impaired semen quality. The investigators believe our new human data supported by the results from the VD deficient and VDR KO animal studies and the high proportion of VD deficient Danish men provide sufficient evidence to initiate a randomized clinical trial of VD supplementation to infertile men. Infertile men have also have unfavorable altered levels of sex hormones and higher mortality than fertile men. Since VD deficiency is associated with increased mortality, regulation of aromatase, immune system, bone metabolism, glucose metabolism, cardiovascular system etc. our suggested clinical trial may also be able to evaluate several secondary endpoints in addition to the potential effect on semen quality.
Conditions
- Male Infertility
Interventions
Cholecalciferol and calciumDrug
Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
PlaceboOther
microcrystalline cellulose maltodextrin Arachidis oil
Primary outcomes
What the sponsor says the trial is designed to measure.
- semen qualityTime frame: 150 days
- sperm motilityTime frame: 150 days
- sperm morphologyTime frame: 150 days
- sperm concentrationTime frame: 150 days
- total sperm countTime frame: 150 days
- semen volumeTime frame: 150 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.